Hospital
West Penn Allegheny Health System INC.
West Penn Allegheny Health System INC. was paid $8.24M by Medicaid between Nov 2019 and Dec 2024, across 225 billing codes. Its largest line is G0378, Hospital observation service, per hour — 30% of everything it billed.
33Billing provider infoWEST PENN ALLEGHENY HEALTH SYSTEM INC.
MONROEVILLE, PA 15146
MONROEVILLE, PA 15146
33aNPI1679592380assigned 07/19/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.24M
24GClaims282,261
24DCodes billed225
24AFirst – last monthNov 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#41 of 154
Median peer was paid$2.82M
This provider vs. median2.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 218 | $12K | |
| 2020 | 29,146 | $630K | |
| 2021 | 125,183 | $3.07M | |
| 2022 | 41,136 | $1.41M | |
| 2023 | 52,387 | $1.82M | |
| 2024incomplete | 34,191 | $1.31M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0378 | Hospital observation service, per hour | 30% | 3,043 | 2,784 | $2.51M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 25% | 13,340 | 12,614 | $2.04M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 6,091 | 5,940 | $883K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 6,665 | 6,519 | $847K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 1,929 | 1,862 | $198K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 6,994 | 6,590 | $109K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 2,521 | 2,307 | $96K |
| 80053 | Comprehensive metabolic panel | 1.1% | 13,281 | 11,879 | $87K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.0% | 1,297 | 1,271 | $85K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 22,096 | 19,031 | $72K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,126 | 1,078 | $67K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | <1% | 978 | 629 | $66K |
213 more codes
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,747 | $66K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,096 | $64K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,387 | $63K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,442 | $58K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,329 | $55K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,041 | $36K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,062 | $35K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,786 | $31K |
| 70498 | <1% | 313 | $29K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 280 | $27K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 229 | $25K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,042 | $23K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 225 | $21K |
| 84484 | <1% | 4,089 | $21K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 173 | $20K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 300 | $19K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 280 | $17K |
| 80299 | <1% | 761 | $17K | |
| 84703 | <1% | 2,734 | $17K | |
| 0002A | <1% | 359 | $16K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 419 | $16K |
| 87481 | <1% | 431 | $16K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,729 | $15K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 506 | $15K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 328 | $15K |
| 80061 | Lipid panel | <1% | 1,149 | $14K |
| 84702 | <1% | 1,086 | $13K | |
| 83880 | <1% | 925 | $13K | |
| 80050 | General health panel | <1% | 357 | $13K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 431 | $12K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 414 | $12K |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 228 | $11K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,428 | $10K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 55 | $10K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 147 | $10K |
| 0001A | <1% | 357 | $10K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,020 | $9K |
| 86803 | <1% | 471 | $9K | |
| 83735 | <1% | 2,705 | $9K | |
| 70496 | <1% | 116 | $9K | |
| 96376 | <1% | 1,705 | $8K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 456 | $8K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 668 | $8K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 100 | $7K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,039 | $7K |
| 76642 | <1% | 140 | $7K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,579 | $7K |
| 83690 | <1% | 2,644 | $7K | |
| 70486 | <1% | 105 | $6K | |
| 84999 | <1% | 2,347 | $6K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 503 | $6K |
| 93971 | <1% | 150 | $6K | |
| 81001 | <1% | 3,440 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 563 | $6K |
| 83605 | <1% | 1,592 | $6K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 992 | $6K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 294 | $5K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 169 | $5K |
| 76830 | Ultrasound, transvaginal | <1% | 128 | $5K |
| 86850 | <1% | 783 | $4K | |
| 86780 | <1% | 252 | $4K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 165 | $4K |
| 84439 | <1% | 520 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 289 | $4K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 32 | $4K |
| 87340 | <1% | 233 | $3K | |
| 87070 | <1% | 526 | $3K | |
| 80076 | <1% | 521 | $3K | |
| 85730 | <1% | 1,073 | $3K | |
| 85379 | <1% | 533 | $3K | |
| 86762 | <1% | 132 | $3K | |
| 85027 | <1% | 736 | $3K | |
| 82570 | <1% | 397 | $3K | |
| 93975 | <1% | 45 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,632 | $3K |
| 73610 | <1% | 209 | $3K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 365 | $3K |
| 84466 | <1% | 199 | $3K | |
| 77066 | Tomosynthesis, mammo | <1% | 28 | $3K |
| 87563 | <1% | 169 | $3K | |
| 85610 | <1% | 1,439 | $3K | |
| 81003 | <1% | 1,212 | $2K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 76 | $2K |
| 87081 | <1% | 442 | $2K | |
| 82550 | <1% | 622 | $2K | |
| 82728 | <1% | 235 | $2K | |
| 87205 | <1% | 529 | $2K | |
| 86900 | <1% | 792 | $2K | |
| 87186 | <1% | 322 | $2K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 82 | $2K |
| 86901 | <1% | 785 | $2K | |
| 73630 | <1% | 222 | $2K | |
| 84145 | <1% | 236 | $2K | |
| 87040 | <1% | 297 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,830 | $2K |
| 73560 | <1% | 206 | $2K | |
| 93017 | <1% | 105 | $2K | |
| 82553 | <1% | 411 | $2K | |
| 82043 | <1% | 190 | $2K | |
| 76801 | <1% | 47 | $2K | |
| 84100 | <1% | 572 | $2K | |
| 82607 | <1% | 223 | $2K | |
| 73130 | <1% | 197 | $2K | |
| 80320 | <1% | 260 | $2K | |
| 84550 | <1% | 249 | $2K | |
| 73030 | <1% | 135 | $2K | |
| 83615 | <1% | 220 | $1K | |
| 71250 | <1% | 35 | $1K | |
| 83540 | <1% | 204 | $1K | |
| 82805 | <1% | 94 | $1K | |
| 80349 | <1% | 141 | $1K | |
| 90715 | <1% | 284 | $1K | |
| 87480 | <1% | 41 | $1K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 30 | $1K |
| 87077 | <1% | 169 | $1K | |
| 87660 | <1% | 41 | $1K | |
| 93970 | <1% | 30 | $1K | |
| 72131 | <1% | 38 | $1K | |
| 82565 | <1% | 232 | $971.70 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,807 | $960.25 |
| 82962 | <1% | 1,466 | $958.89 | |
| 86140 | <1% | 400 | $937.60 | |
| 81025 | <1% | 494 | $917.18 | |
| 86618 | <1% | 46 | $909.45 | |
| 85652 | <1% | 417 | $853.82 | |
| J3490 | Unclassified drugs | <1% | 3,172 | $816.34 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,819 | $767.05 |
| 87075 | <1% | 113 | $750.78 | |
| 76536 | <1% | 12 | $657.71 | |
| 73502 | <1% | 52 | $636.22 | |
| 87147 | <1% | 202 | $585.17 | |
| 76775 | <1% | 14 | $576.60 | |
| 80329 | <1% | 118 | $558.36 | |
| 87510 | <1% | 28 | $556.92 | |
| 72100 | <1% | 39 | $555.33 | |
| 84156 | <1% | 135 | $549.30 | |
| 83001 | <1% | 25 | $547.01 | |
| 86592 | <1% | 119 | $522.71 | |
| 73110 | <1% | 74 | $519.00 | |
| 88342 | <1% | 15 | $399.18 | |
| 77062 | <1% | 13 | $359.52 | |
| 74018 | <1% | 30 | $351.90 | |
| 84146 | <1% | 12 | $347.04 | |
| 59025 | Fetal non-stress test | <1% | 74 | $333.00 |
| 0003A | <1% | 12 | $324.00 | |
| 82746 | <1% | 57 | $317.83 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 53 | $306.15 |
| 82950 | <1% | 38 | $304.36 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,802 | $303.82 |
| 73590 | <1% | 31 | $289.32 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 312 | $248.78 |
| J1815 | Injection, insulin, per 5 units | <1% | 1,852 | $231.59 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,224 | $211.50 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,467 | $210.80 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,579 | $200.07 |
| 73562 | <1% | 15 | $189.16 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,242 | $180.07 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,162 | $175.11 |
| 72040 | <1% | 13 | $156.85 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 834 | $152.82 |
| 97162 | <1% | 144 | $152.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,568 | $147.03 |
| 86038 | <1% | 12 | $128.20 | |
| 87210 | <1% | 40 | $116.49 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,797 | $112.29 |
| 94760 | <1% | 464 | $107.47 | |
| 88304 | <1% | 36 | $98.38 | |
| 97166 | <1% | 166 | $95.98 | |
| 97165 | <1% | 29 | $92.60 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 389 | $75.96 |
| 99152 | <1% | 39 | $73.06 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 61 | $70.56 |
| 87088 | <1% | 12 | $70.39 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,751 | $68.04 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 266 | $63.86 |
| 73080 | <1% | 13 | $63.25 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 12 | $61.10 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,421 | $55.45 |
| 82140 | <1% | 31 | $49.22 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 12 | $47.88 |
| 82330 | <1% | 26 | $42.89 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 187 | $38.92 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 542 | $36.87 |
| 95816 | <1% | 15 | $29.70 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 366 | $27.18 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 28 | $24.74 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,834 | $18.90 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 19 | $17.17 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 143 | $17.16 |
| 85018 | <1% | 17 | $16.62 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 298 | $16.42 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 416 | $15.14 |
| 97161 | <1% | 68 | $12.37 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 270 | $10.83 |
| A9270 | Non-covered item or service | <1% | 33,739 | $10.53 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,425 | $10.10 |
| S0030 | Injection, metronidazole, 500 mg | <1% | 62 | $6.66 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 114 | $6.44 |
| J7999 | Compounded drug, not otherwise classified | <1% | 133 | $3.47 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,192 | $0.09 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 17 | $0.00 |
| 97116 | 0% | 23 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 109 | $0.00 |
| 0004A | 0% | 17 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 36 | $0.00 |
| C1769 | Guide wire | 0% | 12 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 186 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 33 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 105 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 61 | $0.00 |
| 82077 | 0% | 16 | $0.00 | |
| 97535 | Self-care/home management training, each 15 minutes | 0% | 17 | $0.00 |
| 94762 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFRIES, RICK (VICE PRESIDENT, FINANCE)
Parent organizationTHE WESTERN PENNSYLVANIA HOSPITAL
| Provider | Location | Paid |
|---|---|---|
| Jefferson Regional Medical Center | Clairton, PA | $12.73M |
| West Penn Allegheny Health System INC | Pittsburgh, PA | $12.69M |
| West Penn Allegheny Health System INC. | Pittsburgh, PA | $10.81M |
| Alle-Kiski Medical Center | Natrona Heights, PA | $6.09M |
| Canonsburg General Hospital | Canonsburg, PA | $2.97M |
| Grove City Medical Center | Grove City, PA | $2.17M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.